.....
Just to add, either way, they will chrun through for couple for days as expected.
passiton, i agree, but currenlty AIM is common stock (the dog), and we shoud not let the tail wag the dog. Hence why the company wanst to cancel USA ADR stock and move to NASDAQ common stock only (AIM common becomes NAS common). This will give single truth and add huge value to the shareholders. Offcourse they can just be on AIM, but major shareholder is New York bank with 33mill shares, s o that may be the reason.
Either way for now lets not the let dog wag the tail, if push comes to shove - which i think it will.
agree Sirjames, however not worried by daily flactuations, and UK Aim stock leads usa from here, as USA stock is adr (made up of common uk shares) where as shares on AIM are the master common stock. Common stock will drive usa as more following/ interest. imho.
In addition to the lastest Covid-19 development. As mentioned before said they small fish playing big, and very disruptive to big biotec's/phama's with current pipeline of advanced developments in major diseases and big money market niches. Very overlooked and oversold company, even without Covid-19 development. Can see this traded to much higher multiples to current pps. enjoy.
Tiziana (TILS) focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 mAbs in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as crohn's disease (CD), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
And note, non of aim companies related to Covid-19 have this kind of advanced pipeline and looking to disruptive major phama's. TILS management are clean cut and have know-how (they play big for sure). And couple of their scientist and co-founder have proven this in the past. So pretty pleases with things going forward. This long weekend and lock donw provided ample opp to do the ealry research.
Aos noted 58% of TILS shares are not in public hands, leaving only 42% for grabs. hence very low float. so when ot moves it moves big time. £4 is just around corner. imho. do your own dd, enough info has been provided this weekend 9rememeber this weekend going forward). all the best.
In addtion to Covid-19 development.....major catylsy going forward, also see below of the current pipeline of market disruptive drug/ treatments and results to date. These are professionals, and going through FDA for big stuff (££££)
On 22 July, 2019, the Group announced the preliminary topline clinical data from a Phase 2a trial of Milciclib as a monotherapy in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The primary endpoint of the study was overall safety. Under compassionate use, a few patients continued with total treatment for up to 16 months. Overall, treatment with Milciclib was well-tolerated and no drug-related deaths were recorded. Secondary endpoints of efficacy including progression-free survival (PFS) and time to progression (TTP) are currently being evaluated and will subsequently be reported.
•On 4 September, 2019 the Group announced additional positive Phase 2a clinical data exhibitingimpressive clinical activity of Milciclib monotherapy in patients with advanced Sorafenib-resistant or -intolerant patients with unresectable or metastatic hepatocellular carcinoma (HCC).
•On 16 September, 2019 the Group announced that the U.S. Food and Drug Administration (FDA) has allowed the initiation of a Phase I clinical trial in healthy volunteers using a novel oral enteric-coated capsule formulation of Foralumab, a ful ly human monoclonal antibody (mAb), in collaborationwith the Brigham and Women’s Hospital (BWH), Harvard Medical School, Boston, MA. This is thefirst clinical trial in which Foralumab will be administered orally to healthy subjects. The objective is to develop orally administered Foralumab for treatment of autoimmune and inf lammatory diseases.
''In the current situation with overwhelmed intensive care units and overcrowded emergency rooms, correct triage of patients in need of intensive care is crucial. Our study shows that IL-6 is an effective marker that might be able to predict upcoming respiratory failure with high accuracy and help physicians correctly allocate patients at an early stage. All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Acknowledgement: We thank Oliver T. Keppler, the Task Force Corona at the University Hospital, LMU Munich and all CORKUM investigators as well as all health care workers for their outstanding service.
Swevesm just very excited, we may have found gem/ multi bagger - just like we did with ncyt :). made 110k on ncyt (got stoped at £2 but who cares, still ok). so a bit excited here... and doing as much home work as i can, and sharing with like minded investors / traders. I know pps flactuate either way, so getting ready with good research always helps to hold and add etc. hard to have balz of steal in ncyt. I said a number of times back then :)
While we are on price targets, ncyt also had price of £4+ following potential Covid test when at 70p....and people said it won;t be achieved. Well it has.
And SNG has recent broker target of 60p. Go see. some people, don't want to take in research, good info. and later they say only if they had bought a, b, c or held that x,y,z they could have retired! :)
I know SNG has already gone up 200% which is good, but way are you scared of broker target of £4 for TILS which was set before Covid-19 find by the company, and now the patent to protect their find and move forward.
This was a very good news this week - the index will over the commig weeks/ months
Also ''Iamrich'' about to go on filter, taking no-sense as always. Already explained to him that SNG is being tested for flu only, where as TILS going straght for Covid-19 infections and simliar has shown it has saved lives i China and recent on napals China fda has approved simliar to be used in china. Also TILS has realised they are sitting on better treatement that does not need to be used on mouse/monkies as Roche are doing, but can be tested direct in humans. Some people don't seem to get this point.
Also TILS is down 80% from high, so can multi-bag a few times just reaching the high :) / jave some in SNG and Drivegen but they gone uo 200% already alomost reaching peak of their mkt caps for the product they have going for them ....so i expect correction there.
10/2019 - Laidlaw and HC Wainwright Set Price Target Buy $20.00 - following phase 2 - Cancer treatment
Now with Covid-19 in the pipeline and a major patent in the works - expect this figure much higher, so £4 not along short by any means.
CytoSorbents' EBP device wins emergency OK to treat COVID-19 patients - this device is used to prurify blood at very late stage. However how about a treatment that stops and kills the actual Covid-19 infection (specific protien mentioned in the rns) in the lungs before it reaches and destory the blood and other organs. Thats what TILS treatment has been reported to do. The more you look into this the more compelling it gets.
Bottmzup - thats how its works, the company says what they have, and wigh funding push ahead. Rememeber when ncyt did the interview.....everyone thought he was clown. then the placing/warrnts etc. And people said, so many companies have test, the chinese had faster test, and so and so. :) - you don't get multi bags watching shares go up....and/or then buying at £4+ hoping for £8...
They are taking Alan Greens advise a few weeks ago. :)
We are adding Tiziana Life Sciences to the index following news the biotechnology company has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer.
Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.
But you need to price stocks with a view of potential. You can wait, like many did elsewhere (ncyt comes to mind, and that was a test). The next phase is treatment/vaccines etc. With companies like TILS their treatment is needed despite vaccines for Covid-19. Alot has already been said about that.
The main thing , TILS is not one trick pony, so very good trade and meduim/ long term investement. So if you are serious about trading/ investing, TILS is stellar investement, you will never the lose the house on it at this level, and going forwards. :)
wait for the rns, when you start seeling code 1's gear up :) - Its Covid related so expect very soon. but my guess the company is working on testing plan on live Covid-19 cases. Best if people get treated now, even one life is saved is saved its worth it. The thing less effective treatment has saved lives in china and napel - which made the baord and big money jump. So the TILS baord will be pushing forward.
Did you anyone one of you guys, buy ELM mentioned 2 weeks weeks at 40p, now 60p. Holding since 25p, may sell 50%. Good on you if you did buy.
ESL, will move just needs a bit more time. Let you when back in. glta.